The effect of radioimmunotherapy using murine monoclonal antibody KIS1 on esophageal squamous cell carcinoma-bearing nude mice

Surgery Today ◽  
1997 ◽  
Vol 27 (11) ◽  
pp. 1026-1034 ◽  
Author(s):  
Teruhiko Fujii ◽  
Hideaki Yamana ◽  
Yuji Toh ◽  
Uhi Toh ◽  
Hiromasa Fujita ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Squamous Cell Carcinoma ◽  
Esophageal Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Nude Mice ◽  
Murine Monoclonal Antibody

Characterization of a Murine Monoclonal Antibody against Human Esophageal Squamous Cell Carcinoma-Associated Antigen

1998 ◽  
Vol 84 (5) ◽  
pp. 578-582 ◽  
Author(s):  
Jagdish S. Nadkarni ◽  
Pushpalaxmi R. Bhadsavle ◽  
Vivek S. Chitnis ◽  
Jayshree J. Nadkarni ◽  
Jitendra S. Vyas ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Squamous Cell Carcinoma ◽  
Esophageal Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Cell Line ◽  
Squamous Cell ◽  
Murine Monoclonal Antibody ◽  
Benign Tumors ◽  
Scatchard Analysis ◽  
Histopathological Diagnosis

A murine monoclonal antibody (MAb) 2G3 of the lgG1 type was raised using the human esophageal squamous cell carcinoma (SCC) cell line TE-2. Immunoblotting with 2G3 indicated that the antigen recognized by 2G3 has a molecular weight of 34 kD. Its activity was evaluated by immunoperoxidase and immunofluorescence on frozen and paraffin sections of various normal tissues, normal and benign tumors as well as various established cell lines. The pattern of reactivity revealed that the antigen recognized by 2G3 was expressed mainly by esophageal SCC. The only exception was represented by malignant breast tumors, where it reacted weakly. Scatchard analysis using 125I-labelled 2G3 showed that TE-2 has approximately 7.5 times more binding sites than the MCF-7 breast cancer cell line. The use of this new MAb is therefore proposed for the histopathological diagnosis of esophageal SCC.

A single-arm, open phase II clinical trial of anti-programmed death-1 antibody SHR-1210 combined with nimotuzumab as second-line treatment of advanced esophageal squamous cell carcinoma.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. TPS4147-TPS4147
Author(s):  
Feng Wang ◽  
Xiangrui Meng ◽  
Qingxia Fan
Keyword(s):  
Clinical Trial ◽  
Monoclonal Antibody ◽  
Squamous Cell Carcinoma ◽  
Esophageal Cancer ◽  
Esophageal Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Phase Ii ◽  
Squamous Cell ◽  
Second Line ◽  
Antitumor Effects

TPS4147 Background: Approximately 40% of patients (pts) with esophageal cancer are diagnosed with advanced unresectable or metastatic disease; the 5-year survival rate for advanced disease is 5%. No standard therapy is available in China for Advanced Esophageal Squamous Cell Carcinoma(ESCC) patients progressed after first-line chemotherapy.Inhibition of programmed cell death protein-1 (PD-1) has demonstrated promising antitumor activity and manageable safety in pts with advanced unresectable or metastatic ESCC. SHR-1210, a humanized IgG4 monoclonal antibody, has high affinity and specificity for PD-1 molecule. SHR-1210 was generally well tolerated and had preliminary antitumor effects in pts with solid tumors, including ESCC. Nimotuzumab, a humanized anti-epidermal growth factor receptor monoclonal antibody h-R3, has been shown to be effective and safe in the treatment of head and neck cancer,non-small cell lung cancer (NSCLC) and esophageal Cancer in several phase II studies.The purpose of this study is to observe and evaluate the efficacy and safety of anti-PD-1 antibody SHR-1210 combined with nimotuzumab as second-line therapy in patients with advanced ESCC. Methods: Patients, age 18-75, with measurable tumor lesion, failed in or progression after 1st line chemotherapy, were enrolled in this study.Patients received SHR-1210 200 mg once every 2 weeks (Q2W) combined nimotuzumab 200 mg weekly until disease progression, death or unacceptable toxicity.Assessments included response by RECIST v1.1 every 6 wks and safety (physical examination, vital signs, ECOG PS, laboratory tests).The primary endpoint is the objective response rate (ORR),and the secondary end points include the diseases control rate (DCR),duration of response (DOR),progression-free survival (PFS),and overall survival(OS). Additionally, we try to identify biomarker to predict efficacy of SHR-1210 and Nimotuzumab with target capture sequencing and gene expression profile as exploratory endpoints. Clinical trial information: NCT03766178.

scholarly journals Detection of Esophageal Squamous Cell Carcinoma by Cathepsin B Activity in Nude Mice

PLoS ONE ◽  
2014 ◽  
Vol 9 (3) ◽  
pp. e92351 ◽  
Author(s):  
Wei Ma ◽  
Lie Ma ◽  
Hong Zhe ◽  
Cihang Bao ◽  
Nana Wang ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Esophageal Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Nude Mice ◽  
Cathepsin B

Localization and imaging of radiolabelled monoclonal antibody against squamous-cell carcinoma of the head and neck in tumor-bearing nude mice

1989 ◽  
Vol 44 (3) ◽  
pp. 534-538 ◽  
Author(s):  
J. J. Quak ◽  
A. J. M. Balm ◽  
J. G. P. Brakkee ◽  
R. J. Scheper ◽  
H. J. Haisma ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Squamous Cell ◽  
Nude Mice ◽  
Tumor Bearing

Detection of Squamous Cell Carcinoma Xenografts in Nude Mice by Radiolabeled Monoclonal Antibody E48

1991 ◽  
Vol 117 (11) ◽  
pp. 1287-1291 ◽  
Author(s):  
J. J. Quak ◽  
M. Gerretsen ◽  
A. H. G. J. Schrijvers ◽  
C. J. L. M. Meijer ◽  
G. A. M. S. van Dongen ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Nude Mice
Sign in / Sign up

Export Citation Format

Share Document